Cantex Pharmaceuticals and Headlamp Health are teaming up to fast-track an oral treatment for the debilitating depression and fatigue that affects many people living with multiple sclerosis (MS). The partnership centers on the development of azeliragon, an experimental therapy. By leveraging Headlamp’s Lumus AI platform, the companies plan to analyze existing data to predict which MS patients […]

The post New partnership uses AI to fast-track oral pill for MS depression and fatigue appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com